Examination of a dual-pathway strategy to develop autologous and off-the-shelf iPSC-derived Parkinson's therapies and industrial scalability.
Key Takeaways
- Dual Breakthrough in iPSC Parkinson's Therapy News provided by Unixell Biotech Jun 24
- ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S
- Paired with the prior IND approval from China's National Medical Products Administration (NMPA)